Health and Healthcare
BioCryst Crushes It on Rare Immune Disorder Drug Trial
Published:
Last Updated:
BioCryst’s treatment, BCX4161, is a novel, selective inhibitor of plasma kallikrein in development for prevention of attacks in patients with HAE. The drug suppresses the body’s production of bradykinin, which is a cause of acute swelling attacks in HAE sufferers.
BioCryst has been on something of a tear over the past 12 months. The share price is up more than 460%, and the stock reached its 52-week high shortly after the announcement in early March of a successful Phase 1 clinical trial of BCX4161.
Shares were up more than 11%, after rising as much as 20% earlier Tuesday morning. The stock was trading at $10.07 a half-hour after the open. The 52-week range is $1.42 to $13.33.
ALSO READ: Why You Buy Big Pharma If the Market Crashes
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.